Tachyphylaxis/ tolerance to antidepressive medications: A review

Israel Journal of Psychiatry and Related Sciences

Volumn 48, Issue 2, 2011, Pages 129-135

  Katz, Gregory ^a  

^a Kfar Shaul Hospital   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

DEPRESSION; HUMAN; TACHYPHYLAXIS;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; TACHYPHYLAXIS;

EID: 79959559452     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Stedman's Medical Dictionary (27th ed.). Philadelphia: Lippincott, Williams, and Wilkins, 2000.
2. Leib J, Balter A. Antidepressant tachyphylaxis. Med Hypothesis 1984; 15:279-291.
3. Mann J. Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition. J Clin Psychopharmacol 1983;3:363-366.
4. Zetin M, Aden G, Moldawsky R. Tolerance to amoxapine antidepressant effects. Clin Ther 1983; 5:638-643.
5. Solomon DA, Leon AC, Mueller TI, Coryell W, Teres JJ, Posternak MA, Judd LL, Endicott J, Keller MB. Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry 2005; 66:283-290.
6. Rothschild A. The Rothschild Scale for Antidepressant Tachyphylaxis. Poster presented at 159th Annual Meeting of the American Psychiatric Association, May 20-25, 2006, Toronto, Canada.
7. Rothschild A. The Rothschild Scale for Antidepressant Tachyphylaxis: Reliability and validity. Compr Psychiatry 2008; 49: 508-513.
8. Ferrier N. Treatment-resistant mood disorders. Br J Psychiatry 2002; 181: 264.
9. Jefferson J. It looks like "bradyphylaxis" to me. J Clin Psychiatry 2005; 66: 1076.
10. Byrne S, Rothschild A. Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments. J Clin Psychiatry 1998; 59: 279-288.
11. Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: The role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry 2003; 64 Suppl 15:13-17.
12. Quitkin FM, Stewart JW, McGrath PJ, Nunes E, Ocepek-Welikson K, Tricamo E, Rabkin JG, Klein DF. Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993; 150; 562-565.
13. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial. JAMA 1998; 280: 1665-1672.
14. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65:44-49.
15. McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, Fava M, Cheng J, Petkova E. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 2006; 163:1542-1548.
16. Posternak MA, Zimmerman M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: A retrospective study. J Clin Psychiatry 2005; 66:705-707.
17. Cohen BM, Baldessarini RJ. Tolerance to therapeutic effects of antidepressants. Am J Psychiatry 1985; 142:489-490.
18. Rapport DJ, Calabrese JR. Tolerance to fluoxetine. J Clin Psychopharmacol 1993; 13:361.
19. Wijkstra J, Burger H, van den Broek WW, Birkenhger TK, Janzing JG, Boks MP, Bruijn JA, van der Loos ML, Breteler LM, Verkes RJ, Nolen WA. Long-term response to successful acute pharmacological treatment of psychotic depression. J Affect Disord J Affect Disord 2010;123:238-242.
20. Kornstein SG. Beyond remission, rationale, and design of the prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) Study. CNS Spectr 2006; 11:12(Suppl 15):28-34.
21. Serna MC, Cruz I, Real J, Gasco E, Galvan L. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry Eur Psychiatry 2010;25:206-213.
22. Zimmerman M, Thongy T. How often do SSRIs and other newgeneration antidepressants lose their effect during continuation treatment? Evidence suggesting the rate of true tachyphylaxis during continuation treatment is low. J Clin Psychiatry 2007; 68:1271-1276.
23. Thase MA. Preventing relapse and recurrence of depression: A brief review of therapeutic options. CNS Spectr 2006; 11:12-21.
24. Serretti A, Artioli P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 2004; 4:233-244.
25. Neumeister A, Hu XZ, Luckenbaugh DA, Schwarz M, Nugent AC, Bonne O, Herscovitch P, Goldman D, Drevets WC, Charney DS. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry 2006; 63: 978-986.
26. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:722-726.
27. Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 2003; 64:123-133.
28. Muraki I, Inoue T, Hashimoto S, Izumi T, Koyama T. Effect of different challenge doses after repeated citalopram treatment on extracellular serotonin level in the medial prefrontal cortex: In vivo microdialysis study. Psychiatry Clin Neurosci 2008; 62:568-574.
29. Cornelisse LN, Van der Harst JE, Lodder JC, Baarendse PJ, Timmerman AJ, Mansvelder HD, Spruijt BM, Brussaard AB. Reduced 5-HT1Aand GABAB receptor function in dorsal raph neurons upon chronic fluoxetine treatment of socially stressed rats. J Neurophysiol 2007; 98:196-204.
30. Güther L, Liebscher S, Jankel M, Oehler J. Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group- and isolationhoused mice. Eur J Pharmacol 2008; 593: 49-61.
31. Kalant H. Drug tolerance and sensitization: A pharmacological overview. In Goudie A, Oment-Oglesby M, eds. Psychoactive drugs: Tolerance and sensitization. Clifton, N.J.: Human Press, 1989.
32. Amsterdam J, Williams D, Michelson D, Adler LA, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology 2009; 59:227-233.
33. Charlier C, Pinto E, Ansseau M, Plomteux G. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 2000; 15: 453-459.
34. Mancama D, Kerwin RW. Role of pharmacogenomics in individualizing treatment with SSRIs. CNS Drugs 2003; 17:143-151.
35. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. Discontinuation consensus panel. J Clin Psychiatry 1997; 58 Suppl 7:5-10.
36. Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 2007;67:1657-1663.
37. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: A randomized study. J Psychopharmacol 2008; 22:330-332.
38. Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42:757-763.
39. Himei A, Okamura T. Discontinuation syndrome associated with paroxetine in depressed patients: A retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 2006; 20:665-672.
40. Perahia DG, Kajdasz DK, Desaiah D, Haddad PM. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005; 89: 207-212.
41. Baboolal NS. Venlafaxine withdrawal syndrome: Report of seven cases in Trinidad. J Clin Psychopharmacol 2004; 24:229-231.
42. Stone TE, Swanson C, Feldman MD. Venlafaxine discontinuation syndrome and suicidal ideation: A case series. J Clin Psychopharmacol 2007; 27:94-95.
43. Campagne DM. Venlafaxine and serious withdrawal symptoms: Warning to drivers. MedGenMed 2005; 6: 22.
44. Sir A, D'Souza RF, Uguz S, George T, Vahip S, Hopwood M, Martin AJ, Lam W, Burt T. Randomized trial of sertraline versus venlafaxine XR in major depression: Efficacy and discontinuation symptoms. J Clin Psychiatry 2005; 66:1312-1320.
45. Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42:757-763.
46. Quaglio G, Schifano F, Lugoboni F. Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse. Addiction 2008; 103:1572-1574.
47. Harvey BH, Retief R, Korff A, Wegener G. Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: Role of 5HT 2A/C-receptors. Metab Brain Dis 2006; 21:211-220.
48. Constantinescu C. Two unusual cases of psychotropic drug dependence (imipramine and reserpine). Agressologie 1978; 19:179-180.
49. Toro P, Nores JM, Remy JM. Clomipramine dependence in a drug addict. 1st case. Presse Med 1989; 28:132.
50. Eyer F, Jetzinger E, Pfab R, Zilker T Withdrawal from high-dose tranylcypromine. Clin Toxicol (Phila) 2008; 46: 261-263.
51. Sharma V. Loss of response to antidepressants and subsequent refractoriness: Diagnostic issues in a retrospective case series. J Affect Disord 2001; 64:99-106.
52. Amsterdam J, Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 243-261.
53. Amsterdam J, Shultz J. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode? J Affect Disord 2009; 115: 234-240.
54. Nierenberg A, Katz J, Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. Psychtr Clin North Am 2007; 30: 13-29.
55. Byrne S, Rothschild AJ. Psychiatrists' responses to failure of maintenance therapy with antidepressants. Psychiatr Serv 1997; 48: 835-837.
56. Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment: Response to increased fluoxetine dose. J Clin Psychiatry 1995; 56:52-55.
57. Fichtner CG, Jobe TH, Braun BG. Possible therapeutic window for serotonin reuptake inhibitors. J Clin Psychiatry 1994; 55:36-38.
58. Fichtner CG, Jobe TH, Braun BG. Does fluoxetine have a therapeutic window? Lancet 1991;24:520-521.
59. Cain JW. Poor response to fluoxetine: Underlying depression, serotonergic overstimulation, or a "therapeutic window." J Clin Psychiatry 1992; 53: 272-277.
60. Leykin Y, Amsterdam JD, DeRubeis RJ, Gallop R, Shelton RC, Hollon SD. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult Clin Psychol 2007; 75:267-276.
61. Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord 2009; 116:4-11.
62. Papakostas G. Partial response or nonresponse: Switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009; 70[suppl 6]:16-25.
63. Nierenberg A, Katz J, Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am 2007; 30: 13-29.
64. Fava M. Management of nonresponse and intolerance: Switching strategies. J Clin Psychiatry 2000; 61 (suppl 2): 10-12.
65. Papakostas G, Fava M, Thase M. Treatment of SSRI-resistant depression: A meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008; 63: 699-704.